Abstract: An improved ultra-fast cooling system is disclosed for cryopreservation of biomaterials. The ultra-fast cooling system is designed to uniformly vitrify or partially vitrify biomaterials, including but not limited to, human biomaterials, proteins, peptides, cells, stem cells, antibodies, neurons, human tissue, organs, cornea, skin, retina, eggs, sperm, embryos, body fluids, blood, serum, lymph fluid, animal tissue, plant biomaterials, plant tissue, germ plasma, pollen, plant sap, and bioengineered tissue, without cryoprotectants or with a low concentration of cryoprotectants. Cooling rates are sufficient to uniformly cryopreserve biomaterials, and can be used in diagnostic cytology and biological cryofixation applications. Other materials also can be cooled uniformly, such as inorganic materials for processing.

Abstract: Systems and methods are described herein for determining that a patient has indications mild cognitive impairment (MCI) or early stage Alzheimer's disease (AD). Microperimetry is used to assess the functional integrity of the patient's retina. Optical Coherence Tomography is used to assess the structural integrity of the patient's retina. Reductions in the size and function of the patient's retina indicate that the patient may have MCI or early stage AD.

Abstract: A cryoprotective device protects an aqueous biological material from mechanical damage due to ice formation during cryogenic freezing and/or cryostorage by preventing direct contact of the biological material with cell-damaging large ice crystals, the cryoprotective storage device having a housing with an internal cavity. The housing is configured to receive a freezable medium with the biological material within the internal cavity. The housing includes a semi-permeable membrane. The membrane is impermeable to ice crystals that are larger than an average pore size of the membrane to prevent such ice crystals from passing into the internal cavity from outside the housing, such that ice crystals formed in the medium within the housing have a smaller crystal size from ice crystals formed in the medium outside of the housing. As such, the biological material is protected from mechanical damage generated by direct contact with large ice crystals.

Abstract: An improved ultra-fast cooling system is disclosed for cryopreservation of biomaterials. The ultra-fast cooling system is designed to uniformly vitrify or partially vitrify biomaterials, including but not limited to, human biomaterials, proteins, peptides, cells, stem cells, antibodies, neurons, human tissue, organs, cornea, skin, retina, eggs, sperm, embryos, body fluids, blood, serum, lymph fluid, animal tissue, plant biomaterials, plant tissue, germ plasma, pollen, plant sap, and bioengineered tissue, without cryoprotectants or with a low concentration of cryoprotectants. Cooling rates are sufficient to uniformly cryopreserve biomaterials, and can be used in diagnostic cytology and biological cryofixation applications. Other materials also can be cooled uniformly, such as inorganic materials for processing.

Abstract: Systems and methods are described herein for determining that a patient has indications mild cognitive impairment (MCI) or early stage Alzheimer's disease (AD). Microperimetry is used to assess the functional integrity of the patient's retina. Optical Coherence Tomography is used to assess the structural integrity of the patient's retina. Reductions in the size and function of the patient's retina indicate that the patient may have MCI or early stage AD.

Abstract: Systems and methods are described herein for determining that a patient has indications mild cognitive impairment (MCI) or early stage Alzheimer's disease (AD). Microperimetry is used to assess the functional integrity of the patient's retina. Optical Coherence Tomography is used to assess the structural integrity of the patient's retina. Reductions in the size and function of the patient's retina indicate that the patient may have MCI or early stage AD.

Abstract: A method for enhancing amidohydrolase activity of Fatty Acid Amide Hydrolase (FAAH) is disclosed. The method comprising administering a phenoxyacyl-ethanolamide that causes the enhanced activity. The enhanced activity can have numerous effects on biological organisms including, for example, enhancing the growth of certain seedlings.

Abstract: A method for enhancing amidohydrolase activity of Fatty Acid Amide Hydrolase (FAAH) is disclosed. The method comprising administering a phenoxyacyl-ethanolamide that causes the enhanced activity. The enhanced activity can have numerous effects on biological organisms including, for example, enhancing the growth of certain seedlings.

Abstract: A method for enhancing amidohydrolase activity of Fatty Acid Amide Hydrolase (FAAH) is disclosed. The method comprising administering a phenoxyacylethanolamide that causes the enhanced activity. The enhanced activity can have numerous effects on biological organisms including, for example, enhancing the growth of certain seedlings. The subject matter disclosed herein relates to enhancers of amidohydrolase activity.

Abstract: Systems and methods are described herein for determining that a patient has indications mild cognitive impairment (MCI) or early stage Alzheimer's disease (AD). Microperimetry is used to assess the functional integrity of the patient's retina. Optical Coherence Tomography is used to assess the structural integrity of the patient's retina. Reductions in the size and function of the patient's retina indicate that the patient may have MCI or early stage AD.

Abstract: A method for enhancing amidohydrolase activity of Fatty Acid Amide Hydrolase (FAAH) is disclosed. The method comprising administering a phenoxyacylethanolamide that causes the enhanced activity. The enhanced activity can have numerous effects on biological organisms including, for example, enhancing the growth of certain seedlings. The subject matter disclosed herein relates to enhancers of amidohydrolase activity.

Abstract: A guided mode resonance (GMR) sensor that can be used to simultaneously detect an array of analytes. It provides a diagnostic system that can rapidly detect an array of biomarker proteins in patient samples (such as blood, serum or plasma for example) which can be used as an accurate means to conduct a differential analysis of proteins that allows the discrimination of early and late stages of disease, such as metastatic versus primary ovarian serous carcinomas. The GMR sensor can be provided in a compact size such that it can be portable.

Abstract: The present invention includes compositions and methods for screening for a candidate substance with ryanodine receptor (RyR)-modulatory activity, the method including: determining the ion-conducting ability and ability to change the concentration of the free cytoplasmic intracellular Ca2+ by the RyR modulated by Estrogen receptor-? (ER?) in cells or cell membranes expressing RyR and ER? combination with, or in the absence of the estrogen; contacting the cells or cell membranes with a candidate substance capable of modulation the interaction between RyR and ER?; and measuring the RyR mediated ion-conducting ability of the cells or cell membranes to change the concentration of the free cytoplasmic intracellular Ca2+ by the candidate substance, whereby the modulatory activity of the candidate substance on RyR/ER? interaction is determined.

Abstract: The present invention includes compositions and methods for treating diseases of the eye and skin by modulating the amount of intracellular calcium using transdermal or transcorneal delivery of one or more N-acylethanolamines in a carrier.

Abstract: The present invention includes compositions and methods for neuroprotection by modulating intracellular calcium concentrations by administering an effective amount of an N-acylethanolamine to a subject.